CLEVIPREX

This brand name is authorized in Austria, Spain, France, Netherlands, New Zealand, United States

Active ingredients

The drug CLEVIPREX contains one active pharmaceutical ingredient (API):

1 Clevidipine UNII 19O2GP3B7Q - CLEVIDIPINE

Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterialsmooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Read about Clevidipine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
CLEVIPREX Emulsion for infusion	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C08CA16		C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives
Discover more medicines within C08CA16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 76595
Country: FR	Base de données publique des médicaments	Identifier(s): 64628249
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 131032
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 13768
Country: US	FDA, National Drug Code	Identifier(s): 10122-610, 10122-611, 18124-011